Serratus Anterior Block and Erector Spinae Block in Postoperative Analgesia

Evaluation of the Effect of Serratus Anterior Block and Erector Spinae Block on Postoperative Analgesia in Thoracic Surgeries

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04579302

Enrollment

Registered

2020-10-08

Start date

2020-11-01

Completion date

2021-02-28

Last updated

2021-03-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Analgesia

Keywords

Serratus anterior block, Erector spinae block, Postoperative analgesia

Brief summary

90 patients scheduled for thoracic cancer surgeries, allocated in 3 groups for serratus anterior block and erector spinae block and control group. during anaesthesia:total intraoperative fentanyl required will be recorded. After surgery, all patients will be connected to PCA device containing morphine solution, the amount of morphine consumed during the first 24 hours will be recorded.

Detailed description

90 patients scheduled for thoracic cancer surgeries, allocated in 3 groups for serratus anterior block (SAB) and erector spinae block (ESB) and control group. During anaesthesia: total intraoperative fentanyl required will be recorded. After surgery, all patients will be connected to PCA device containing morphine solution, the amount of morphine consumed during the first 24 hours will be recorded. Other secondary outcomes are: numerical rating scales and postoperative pulmonary functions.

Interventions

PROCEDURESerratus anterior block (SAB)

Patients will receive a sonar guided serratus anterior plane block with 20 ml of bupivacaine 0.5%

PROCEDUREErector spinae block

Patients will receive a sonar-guided erector spinae plane block with 20 ml of bupivacaine 0.5%

DRUGSaline (as a placebo)

Patients will receive a sham block with 20 ml saline (as a placebo)

DRUGBupivacaine

bupivacaine

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

SUPPORTIVE_CARE

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Patients with class II physical status (American Society of Anaesthesiologists) , * Age between 18-70 years, * Scheduled for thoracic cancer surgery

Exclusion criteria

* Patient refusal. * Local infection at the site of the block. * Cardiac dysfunction (ejection fraction \<45%). * Significant respiratory disorders. * Preexisting neurological or psychiatric disease. * Allergy to one of the study drugs. * Pregnancy. * Coagulopathy

Design outcomes

Primary

Measure	Time frame	Description
total morphine consumption in first postoperative 24 hours	first 24 postoperative hours	the amount of morphine required to relieve pain will be recorded

Secondary

Measure	Time frame	Description
intraoperative fentanyl requirement	during anaesthesia	the amount of fentanyl required during anaesthesia will be recorded
numerical rating scale	the first 24 postoperative hours	numerical rating scale (from 0 to 10, where 0 represents no pain and 10 represents the worst imaginable pain) will be recorded in different time intervals during the first 24 hours after surgery
pulmonary functions	24 hours after surgery	FVC and FEV1 will be recorded at 24 hours after surgery

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026